PROBLEM

In 2008, Mercedes Mears, a girl from Tacoma, WA, developed a severe allergic reaction on her way to school. Her school had a system in place, the medicine and the training to respond, but Mercedes passed away on her way to the hospital. If the school staff had had a way to know in advance that Mercedes was having a severe allergic attack, they could have responded on time.

SOLUTION

Aibi is a three part system that offers early detection, treatment instruction, and communication between patients and their caretakers. The Aibi system consists of a wearable bracelet that tracks histamine levels on the skin, a redesigned medicine applicator, and a communication system that works over the cellphone emergency alert system.

MARKET OPPORTUNITY

While Auto-Injector manufacturers such as EpiPen and Auvi-Q might be the closest competitors to us, none of them provide a comprehensive systemic solution that addresses the pain points of allergic children, parents, school nurses and teachers, which brings Aibi a huge advantage. Parents have been criticizing the skyrocketing retail prices of both Epipen and Auvi-Q, which has more than 150% increment of prices in a single year, from $240 in 2013 to $400 in 2014 for an Auvi-Q twin pack. The disposable cartridge with two doses of epinephrine in the reusable Aibi’s injector is a promising solution that will radically bring the costs down, providing affordable access to epinephrine auto-injectors for children with severe allergies, besides detecting and alerting at the first place.

TEAM

FOUNDER & DESIGNER

CHIP DONG LIM
DANIEL GALÁN

ADVISORS

HEATHER CLARK, Associate Professor & Researcher, Northeastern University
DR. KAREN KOO, Critical Care Practitioner, Seattle, WA
DR. DAWN LIM, Health Advisor for MaRS Health Ventures, Toronto, Canada

11.8 MILLION
Children in the U.S. with food allergies

EVERY 6 MINUTES
Frequency of allergic children emergencies

$4,184
Annual costs of food allergies

265%
Increase in the rate of hospitalizations over 10 years